Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | NEU2 | Q9Y3R4 | 3/20 | 0.47 |
| ▸ | NEU4 | Q8WWR8 | 2/20 | 0.47 |
| ▸ | NEU3 | Q9UQ49 | 2/20 | 0.47 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.47 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | MAG | P20916 | 2/20 | 0.42 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sialic Acid SCHEMBL22412 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL12391269 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL22879166 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL20299824 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL23366253 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL24274184 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL22279106 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL21067569 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL22943658 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL16802838 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| US-11246878-B2 | Compositions and products for infectious or inflammatory diseases or conditions | B&H BIOTECHNOLOGIES, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-14 | — | — | US | disclosed |
| US-9034844-B2 | 6′-sialyllactose salts and process for their synthesis and for the synthesis of other alpha-sialyloligosaccharides | INALCO S.P.A. (IT) | 2015-05-19 | — | — | US | disclosed |
| WO-2014151523-A1 | COMPOSITIONS AND PRODUCTS FOR INFECTIOUS OR INFLAMMATORY DISEASES OR CONDITIONS | WANG HUIRU (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8658093-B2 | Devices and methods for the detection of analytes | APPLIED BIOSYSTEMS, LLC (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658093-B2 | Devices and methods for the detection of analytes | APPLIED BIOSYSTEMS, LLC (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120071441-A1 | 6'-SIALYLLACTOSE SALTS AND PROCESS FOR THEIR SYNTHESIS AND FOR THE SYNTHESIS OF OTHER ALPHA-SIALYLOLIGOSACCHARIDES | INALCO S.P.A. (IT) | 2012-03-22 | — | — | US | disclosed |
| US-8076292-B2 | Factor VIII: remodeling and glycoconjugation of factor VIII | NOVO NORDISK A/S (DK) | 2011-12-13 | — | — | US | disclosed |
| US-8063015-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-20080050772-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-7297511-B2 | Viricides; heptatis virus; complexing of interferon with glycan | NEOSE TECHNOLOGIES, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-7276475-B2 | Remodeling and glycoconjugation of peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-7265084-B2 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265085-B2 | Glycoconjugation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7226903-B2 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7214660-B2 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-7179617-B2 | Forming a convalent conjugate of a Factor IX peptide, removing X2 or a saccharyl subunit thereof from peptide forming a truncated glycan; contacting truncated glycan with glycosyltransferase and modified sugar donor under conditions suitable for glycosyltransferase to transfer a modified sugar moiety | NEOSE TECHNOLOGIES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070027068-A1 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| US-7157277-B2 | Factor VIII remodeling and glycoconjugation of Factor VIII | NEOSE TECHNOLOGIES, INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11246878-B2 | Compositions and products for infectious or inflammatory diseases or conditions | SI, SLC5A1, FABP2 | NANP 327/4885L3MBTL1 4696/4885NEU2 34/4885 |
| US-20120071441-A1 | 6'-SIALYLLACTOSE SALTS AND PROCESS FOR THEIR SYNTHESIS AND FOR THE SYNTHESIS OF OTHER ALPHA-SIALYLOLIGOSACCHARIDES | ST6GAL1, FUT6, ST3GAL3 | NANP 127/4885L3MBTL1 3410/4885NEU2 12/4885 |
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | F13B, F8, F13A1 | NANP 473/4885L3MBTL1 3461/4885NEU2 136/4885 |
| US-20070027068-A1 | Erythropoietin: remodeling and glycoconjugation of erythropoietin | EPOR, HBG2, HAMP | NANP 1534/4885L3MBTL1 4188/4885NEU2 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.